Picomolar Dichotomous Activity of Gnidimacrin Against HIV-1
Figure 3
Gnidimacrin exhibited highly selective cytotoxicity against HIV-1 chronically infected cells.
ACH-2, U1, and U937 cells were treated with the compounds for three days before the cytotoxicity was determined by using a Promega cell viability assay kit. MT4 and PBMCs were treated with the compounds parallel to the antiviral assays for 4 days and 7 days, respectively. The viability of the cells cultured in the absence of the tested compounds is defined as 100% control. Each data point in the figure represents the average of two independent experiments.